Ameriprise Financial Inc. Invests $668,000 in Dova Pharmaceuticals, Inc. (DOVA)
Ameriprise Financial Inc. acquired a new position in shares of Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 29,969 shares of the company’s stock, valued at approximately $668,000. Ameriprise Financial Inc. owned about 0.12% of Dova Pharmaceuticals at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth about $382,000. Conning Inc. acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth about $1,115,000. Pier Capital LLC acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth about $1,191,000. Sphera Funds Management LTD. acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth about $2,118,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth about $4,458,000. 23.53% of the stock is owned by hedge funds and other institutional investors.
Dova Pharmaceuticals, Inc. (NASDAQ DOVA) opened at $23.13 on Friday. Dova Pharmaceuticals, Inc. has a 52-week low of $16.98 and a 52-week high of $29.99.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.08). During the same quarter in the prior year, the business earned ($0.41) earnings per share. sell-side analysts forecast that Dova Pharmaceuticals, Inc. will post -1.4 EPS for the current fiscal year.
In related news, Director Paul B. Manning acquired 25,870 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was acquired at an average price of $22.30 per share, for a total transaction of $576,901.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Steven M. Goldman acquired 20,169 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The stock was bought at an average price of $22.23 per share, with a total value of $448,356.87. Following the purchase, the director now directly owns 81,158 shares in the company, valued at approximately $1,804,142.34. The disclosure for this purchase can be found here.
TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/ameriprise-financial-inc-invests-668000-in-dova-pharmaceuticals-inc-dova/1694937.html.
A number of analysts recently issued reports on the company. J P Morgan Chase & Co started coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They set an “overweight” rating and a $35.00 price objective for the company. Leerink Swann raised Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 target price for the company in a research report on Tuesday, September 26th. Jefferies Group LLC started coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Zacks Investment Research raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a research report on Wednesday, October 11th.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.